From: New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
List of drugs/agents | Mechanisms of Targeting B7-H3 | Status | Cancer types | Company/organization |
---|---|---|---|---|
B7-H3 TriKE(GTB-5550) | Natural Killer (NK)- cell-based therapy/ADCC | Phase I trial scheduled for 2022 | Multiple myeloma | GT BIOPHARMA, Inc |
TAA06 Injection | B7-H3-targeted CAR-T therapy | FDA approved drug (Orphan drug) | Neuroblastoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd |
131I-omburtamab | radiolabeled mAb targeting B7-H3 | FDA approval? | Neuroblastoma | Y-mAbs Therapeutics, Inc |
Autologous B7-H3-CAR T | B7-H3-targeted CAR-T therapy | Phase I | Epithelial Ovarian Cancer | UNC Lineberger Comprehensive Cancer Center |
DS-7300a | B7-H3 Antibody Drug Conjugate (ADC), | Phase II | Extensive-Stage Small Cell Lung cancer (SCLC) | Daiichi Sankyo, Inc |
MGC018/ MGA012 | Anti-B7-H3 Antibody Drug Conjugate | Phase I/II | Advanced Solid tumors | MacroGenics |
DS-7300a | anti-B7H3 antibody | Phase I/II | Advanced Solid Malignant Tumors | Daiichi Sankyo Co., Ltd |
B7-H3-CAR T | B7-H3-targeted CAR-T therapy | Phase I | Recurrent Glioblastoma Multiforme (GBM) | Crystal Mackall, MD, Stanford University |
Neoadjuvant Nivolumab Plus Ipilimumab | Immunotherapy | Phase 1 | Malignant Peripheral Nerve Sheath Tumor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
177Lu-DTPA-omburtamab | Radioimmunotherapy (a radioactive labelling of a murine monoclonal antibody targeting B7-H3 | Phase I/II | Medulloblastoma | Y-mAbs Therapeutics |